BDSX
Price
$23.87
Change
+$0.47 (+2.01%)
Updated
Oct 20 closing price
Capitalization
251.86M
12 days until earnings call
Intraday BUY SELL Signals
VCYT
Price
$44.79
Change
+$0.99 (+2.26%)
Updated
Oct 20 closing price
Capitalization
3.6B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BDSX vs VCYT

BDSX vs VCYT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BDSX vs. VCYT commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDSX is a Hold and VCYT is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BDSX with price predictions
Oct 20, 2026

BDSX in -5.30% downward trend, falling for three consecutive days on October 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BDSX declined for three days, in 279 of 309 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDSX as a result. In 76 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for BDSX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 42 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

BDSX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BDSX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDSX advanced for three days, in 198 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

BDSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 182 of 198 cases where BDSX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. BDSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.543) is normal, around the industry mean (64.051). P/E Ratio (-7.700) is within average values for comparable stocks, (1.569). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.463) is also within normal values, averaging (9.775).

The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
a Summary for VCYT with price predictions
Oct 20, 2026

VCYT's RSI Indicator recovers from oversold territory

The RSI Indicator for VCYT moved out of oversold territory on September 17, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 17 of the 20 cases the stock moved higher. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where VCYT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 74 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.

VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +3.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 202 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for VCYT turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

VCYT broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VCYT entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. VCYT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.593) is normal, around the industry mean (64.051). P/E Ratio (31.104) is within average values for comparable stocks, (1.569). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).

The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

FUNDAMENTALS RATINGS
BDSX vs VCYT: Fundamental Ratings
BDSX
VCYT
OUTLOOK RATING
1..100
7634
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10075
PRICE GROWTH RATING
1..100
3544
P/E GROWTH RATING
1..100
6595
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BDSX's Valuation (47) in the null industry is in the same range as VCYT (70) in the Biotechnology industry. This means that BDSX’s stock grew similarly to VCYT’s over the last 12 months.

BDSX's Profit vs Risk Rating (100) in the null industry is in the same range as VCYT (100) in the Biotechnology industry. This means that BDSX’s stock grew similarly to VCYT’s over the last 12 months.

VCYT's SMR Rating (75) in the Biotechnology industry is in the same range as BDSX (100) in the null industry. This means that VCYT’s stock grew similarly to BDSX’s over the last 12 months.

BDSX's Price Growth Rating (35) in the null industry is in the same range as VCYT (44) in the Biotechnology industry. This means that BDSX’s stock grew similarly to VCYT’s over the last 12 months.

BDSX's P/E Growth Rating (65) in the null industry is in the same range as VCYT (95) in the Biotechnology industry. This means that BDSX’s stock grew similarly to VCYT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BDSXVCYT
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
70%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 17 days ago
85%
Bullish Trend 1 day ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 9 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 3 days ago
82%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (BDSX: $23.87 vs. VCYT: $44.79)
Brand notoriety: BDSX and VCYT are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BDSX: 39% vs. VCYT: 91%
Market capitalization -- BDSX: $251.86M vs. VCYT: $3.6B
BDSX [@Medical Specialties] is valued at $251.86M. VCYT’s [@Medical Specialties] market capitalization is $3.6B. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Medical Specialties] industry is $20.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BDSX’s FA Score shows that 0 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).

  • BDSX’s FA Score: 0 green, 5 red.
  • VCYT’s FA Score: 0 green, 5 red.
According to our system of comparison, BDSX is a better buy in the long-term than VCYT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BDSX’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 6 bullish TA indicator(s).

  • BDSX’s TA Score: 4 bullish, 5 bearish.
  • VCYT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, VCYT is a better buy in the short-term than BDSX.

Price Growth

BDSX (@Medical Specialties) experienced а -4.52% price change this week, while VCYT (@Medical Specialties) price change was +3.90% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.12%. For the same industry, the average monthly price growth was -4.99%, and the average quarterly price growth was +43.90%.

Reported Earning Dates

BDSX is expected to report earnings on Nov 02, 2026.

VCYT is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Medical Specialties (-1.12% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
BDSX
Daily Signal:
Gain/Loss:
VCYT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IDX9.280.52
+5.94%
VanEck Indonesia Index ETF (IDX)
DIVB69.691.06
+1.54%
iShares Core Dividend ETF (DIVB)
AIVL134.141.36
+1.02%
WisdomTree U.S. AI Enhanced Value Fund (AIVL)
BBBI48.930.05
+0.10%
BondBloxx BBB Rated 5-10 Year Corporate Bond ETF (BBBI)
SMUP1.52-0.06
-3.80%
T-REX 2X Long SMR Daily Target ETF (SMUP)